



SquareX Overview

- **SQX770 PREVENTS** cold sores, herpes labialis episodes or oral herpes outbreaks.
- **Proven effective in 3 independent clinical trials at Harvard and Stanford through Phase 2.**
- Better than Valtrex®, a \$ billion drug
 - Prevents outbreaks instead of just shortening them
 - Reduces severity
 - More convenient dosing--any time vs. only in the first 24 hours. One dose lasts 3 months.
- Huge market: 50 million had a cold sore episode in the previous 12 months, and 7 million had 6 or more episodes in the previous 12 months in U.S. alone.
- **No competition.** No drugs are approved for the indication of preventing cold sore outbreaks, as opposed to treating outbreaks, i.e. shortening duration once an outbreak happens. And prevention is better than treatment.
- Mechanism is to just improve immune function. So likely to work on other diseases.
- Four issued U.S. patents and patent protection and market exclusivity to 2036.
- Experienced and successful team:
 - Founder and CEO had previous successful exit with IGF Oncology.
 - Board has three current and former CEOs and CFOs of public biotech.

Pre-IPO Stock Offering Potential 100x Return



\$3.00 per share,
\$22 million pre-money valuation.



Planned IPO to
NASDAQ
later in 2023.



Current company valuation is
\$119 million
with very conservative assumptions.



At peak revenue,
\$14,700 million valuation
= 670x current stock price.



Estimated valuation
upon FDA approval
\$5,500 million
= 250x current stock price.



Hugh McTavish, Ph.D., Esq.
CEO

☎ 651-356-8953

@ hmctavish@squarex-pharma.com